ClinicalTrials.gov
public full text
Public Domain
A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a single agent in adult subjects with advanced solid tumor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors#349947
- Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors#1086959
- Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors#910225
- A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors#303748
- A Study of IMC-TR1 in Participants With Advanced Solid Tumors#1161661
Record · ID 1307473
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive